

M3D Modern Drug Discovery & Development Summit

Includes six co-located conferences:

2nd Cell & Gene Therapy
2nd Biotechnology Transfer & Commercialization
6th Non-Coding RNA & RNAi Therapeutics
Analytics for Biologics
Protein Kinase inhibitor Design & Screening
Anti-Inflammatory Research & Therapeutics

SEPTEMBER 9-11, 2015 • PHILADELPHIA, PA

Gold Sponsors:



Silver Sponsor:



Media Partners:



BENEFITS

ABOUT

GTChio's **Modern Drug Discovery & Development Summit**, taking place in **September 9-11, 2015** in **Philadelphia, PA**, will bring together an exciting balance of industry, academia and government so that delegates have the unique opportunity to network with colleagues from different sectors and gain fresh perspective on the various research. The summit includes six co-located conferences:

September 9-10, 2015:

6th Non-Coding RNA & RNAi Therapeutics - Emerging areas in RNA research provide great insight into promising therapeutic tools. Delivery has remained a solid focus for understanding how RNA has proven to play a vital and central role in all cellular function. Advances in cell selective delivery and the target abilities of RNAi demonstrate growth and maturity in the field. The excitement and interest that CRISPR brings continues to progress the evolution of genome editing tools.

2nd Biotechnology Transfer & Commercialization - This conference brings together industry leaders from major pharmaceuticals, biotech companies, university technology transfer professionals, and venture capitalists to discuss business incubation, pipeline drivers, partnering, and intellectual property.

2nd Cell & Gene Therapy - Treatment of disease using cell and gene therapy is now a reality. With emerging technologies and new clinical trials being developed and launched at a growing rate, this meeting will discuss the evolving regulatory challenges and pre-clinical requirements, emerging technologies, the development and applications of cell and gene therapy, as well as business models and commercial milestones.

September 10-11, 2015:

Analytics for Biologics - This meeting will provide the tools and the strategies needed to stay ahead in the ever changing and evolving field of biologics. Join this multi-disciplinary forum and network with colleagues from industry and academia to discuss analytical methods and tools that will ensure the most efficient and accurate optimization of biologics.

Anti-Inflammatory Research & Therapeutics - We will focus on understanding the pathways and mechanisms involved in inducing inflammation. Gaining interest in the microbiota spurs conversation about the interaction of bacteria and its relation to controlling inflammation. We will also take a look at key metabolic regulators that are involved in metabolic and growth control pathways.

Protein Kinase Inhibitor Design & Screening - This meeting brings together industry leaders from major pharmaceuticals, biotech companies, and top researchers from academia to provide a timely and critical summary to update significant kinase inhibitors and to better understand current trends for drug design and the screening processes.

CALL FOR PAPERS

To be considered for a short oral presentation, please submit an abstract by **the dates indicated below**. Selected presentations will be based on quality of abstract and availability. Selected abstracts will be notified via email or telephone 2-3 weeks before the conference. Presentation slots fill up fast so please submit your abstract soon.

Click on the following conferences to submit an abstract:

By August 9, 2015

6th Non-Coding RNA & RNAi Therapeutics
2nd Biotechnology Transfer & Commercialization
2nd Cell & Gene Therapy

By August 10, 2015

Analytics for Biologics
Anti-Inflammatory Research & Therapeutics
Protein Kinase Inhibitor Design & Screening

SPONSORS

GOLD



Reaction Biology Corp. is a premiere CRO for radioisotope based drug screening/profiling, assay development and protein production. Drug targets include 457 kinases, >30 methyltransferases, all HDACs and Sirts, Bromodomains, 80+ proteases and more. Key activities include: HTS, IC50 determinations, selectivity profiling, customer-based assay development, chemical library screening/collaboration, cell based assays, etc.

Caprion/Immunecarta is specialized in the design and implementation of immune monitoring assays to assess the phenotypic and functional profiles of immune responses in both pre-clinical and clinical settings (under GLP). They are also leader in Proteomic for the discovery and validation of predictive and prognostic biomarkers using mass spectrometry to rapidly measure the differential expression of proteins from small amounts of biological fluids, tissue, cells and organelles.



Myriad RBM, Inc. is the world's leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides pre-clinical and clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner.

SILVER



SGS Life Science Services is a leading contract service organization providing analytical development, biologics characterization, biosafety, utilities qualification, quality control, and clinical research testing. With the largest wholly-owned network of 25 laboratories in 13 countries, services include: analytical chemistry, microbiology, stability studies, bioanalysis, extractables/leachables, virology, and protein analysis.

SPONSORSHIP OPPORTUNITIES

Connect with high level professionals and renowned scientists in academia in an intimate and highly interactive environment.

- Sponsors/exhibitors will receive the delegate list a week before and a week after the conference.
- Exhibit space is shared between all conferences, providing sponsors/exhibitors access to delegates at all conferences. Exhibitors are located in the same room where all networking functions take place. The coffee, snack stations, breakfast, and reception all occur in this room.
- Your corporate logo will be placed on the cover page of the conference brochures, the proceedings provided to all conference delegates, and on the presentation screen during all breaks to enhance your company's visibility at the event. Your logo will also be placed on the conference website agenda linked to your website.

For sponsorship and exhibit opportunities, please contact:

Amber Kempf
Account Executive
amber.kempf@gtcbio.com

Steve Holmstrom
Account Executive
steve.holmstrom@gtcbio.com

AGENDA AT-A-GLANCE

Day 1 - Wednesday, September 9, 2015

7:00
7:55

*Registration & Continental Breakfast
Welcome & Opening Remarks*

2nd Cell & Gene Therapy

2nd Biotechnology Transfer & Commercialization

6th Non-Coding RNA & RNAi Therapeutics

8:00

Session I
Emerging Technologies

Session I
Bridging the Translation Gap

Session I
RNA Based Therapies

10:00

Morning Networking & Refreshment Break

10:30

Session I
Emerging Technologies (cont.)

Session I
Bridging the Translation Gap (cont.)

Session I
RNA Based Therapies (cont.)

12:00

Lunch Break

1:30

Session II
Pre-clinical Research

Panel Discussion:
Biotechnology Transfer & Licensing

Panel Discussion:
Pharmaceutical Perspectives on the Market

Session II
Advances in Targeted RNA Delivery

Session III
Aptamers in Various Applications

3:00

Afternoon Networking & Refreshment Break

3:30

Session III
Clinical Development

Panel Discussion:
Venture Capital & Partnerships with Emerging Innovators

Session III
Aptamers in Various Applications

6:00

Evening Networking Reception & Poster Session

Day 2 - Thursday, September 10, 2015

7:30

Continental Breakfast

2nd Cell & Gene Therapy

2nd Biotechnology Transfer & Commercialization

6th Non-Coding RNA & RNAi Therapeutics

8:00

Session III
Clinical Development (cont.)

Session IV
Regulatory Challenges

Session II
Commercialization Strategies: Current Trends and Recent Deals

Session IV
RNA Based Therapies part 2

9:45

Morning Networking & Refreshment Break

10:15

Session V
Regulatory Challenges (cont.)

Session VI
Funding / Finance for Cell & Gene Therapy

Panel Discussion:
Commercialization of New Therapeutic Innovations

Panel Discussion:
University and Foundation Relations

Session V
Genome-Editing Technologies

12:00

Conferences Conclude

All times are approximate and subject to changes without notice

AGENDA AT-A-GLANCE

Day 2 - Thursday, September 10, 2015

12:00	<i>Registration</i>		
	Analytics for Biologics	Anti-Inflammatory Research & Therapeutics	Protein Kinase Inhibitor Design & Screening
1:00	Session I Regulatory Standards & Managing Risk Session II Bioconjugates & Antibody Drug Conjugates	Session I Novel Targets in Inflammatory Cytokine Action	Session I Novel Tools and Technological Advances Panel Discussion: Novel Discovery Technologies and Future of Kinase Drug Discovery
3:00	<i>Afternoon Networking & Refreshment Break</i>		
3:30	Session III Biotherapeutic Proteins & Sequence Variants	Session II Novel Targets in Inflammatory Cytokine Action	Session II Target Identification & Validation
6:00	<i>Evening Networking Reception & Poster Session</i>		

Day 3 - Friday, September 11, 2015

7:30	<i>Continental Breakfast</i>		
	Analytics for Biologics	Anti-Inflammatory Research & Therapeutics	Protein Kinase Inhibitor Design & Screening
8:00	Session IV Comparability & Biosimilarity Session V Cell Therapeutics & Immunotherapy	Session III Nucleic Acid Sensing Pathways	Session III Kinase Inhibitor Design and Overcoming Resistance
10:05	<i>Morning Networking & Refreshment Break</i>		
10:40	Session VI Methodology, Tools, & Strategies	Session IV Metabolism and the Immune System	Session III Kinase Inhibitor Design and Overcoming Resistance (cont.)
12:45	<i>Lunch Provided by GTCbio</i>		
1:45	Session VI Methodology, Tools, & Strategies (cont.)	Session V Effects of the Microbiota on Inflammation and Immunity Session VI Cell Death and Clearance Mechanisms	Session IV Biomarkers in Kinase Drug Discovery
3:00	<i>Afternoon Networking & Refreshment Break</i>		
3:30	Session VI Methodology, Tools, & Strategies (cont.)		Session V Novel Therapeutic Areas
4:45	<i>Conferences Conclude</i>		

All times are approximate and subject to changes without notice

KEYNOTE SPEAKERS



SOMAmer-Based Proteomics for Personalized Medicine

Larry Gold
SomaLogic



MicroRNA-Based Therapeutics in Cancer

Frank Slack
Harvard Medical School

DISTINGUISHED SPEAKERS



Selective Activation of Gene Expression by Targeting Long Noncoding RNA

Jim Barsoum
RaNA Therapeutics



Enabling RNA Therapeutics: Unlocking the potential with Locked Nucleic Acids

Mads Aaboe Jensen
Roche Innovation Center Copenhagen



Co-Transfection of crRNA: trRNA Complexes with Cas9 Protein for CRISPR Gene Editing

Mark Behlke
Integrated DNA Technologies



Endothelial Targeted RNA Based Therapies

Michael Khan
Silence Therapeutics



Identifying Aptamers with Defined Cross-Reactivity Using HT-SELEX

Alex Berezhnoy
University of Miami




Session: RNA Based Therapies pt. II

Ryszard Kole
Sarepta Therapeutics



Oligonucleotide Delivery Outside The Liver - Challenges and Emerging Solutions

David Blakey
AstraZeneca



CpG-siRNA Conjugates for Targeting Oncogenic and Immunosuppressive Signaling in Prostate Cancer

Marcin Kortylewski
**Beckman Research Institute
City of Hope National Medical Center**



Session: Genome-Editing Technologies

John Burnett
City of Hope



Oligonucleotide Therapeutics for Human Lymphoma and Leukemia

Prabodhika Mallikaratchy
Lehman College, CUNY



Aptamers for Cell-Targeted Delivery of Therapeutic miRNAs


Vittorio de Franciscis
National Research Council of Italy



Translational Research Funding Opportunities at NINDS

Mary Ann Pellemounter
**Institute of Neurological Disorders and Stroke/
National Institute of Health**

DISTINGUISHED SPEAKERS (cont.)



RNA Smart Drugs for the Treatment of Vascular Injury

Paloma Giangrande
University of Iowa



Session: Genome-Editing Technologies

David Schultz
University of Pennsylvania



Next Generation X-Aptamers for Personalized Nanomedicine in Breast, Pancreatic and Ovarian Cancer

David Gorenstein
University of Texas Health Sciences Center at Houston AM Biotechnologies



Turning Mirror-Image Oligonucleotides into Drugs: The Evolution of Spiegelmer® Therapeutics

Axel Vater
Noxxon Pharma AG



Antisense Oligonucleotide Based Therapy for Genetic Diseases

Tamar Grossman
Isis Pharmaceuticals



Inducing Transcriptional Silencing of HIV by Systemic Delivery of Aptamer-siRNA Chimeras

Marco Weinberg
The Scripps Research Institute



A Novel Small Activating RNA to Cebpa Gene that Treats Fatty Liver, Dyslipidemia And Hyperglycemia

Nagy Habib
MiNA Therapeutics Limited



In vivo Discovery of Targets for Cancer Immunotherapy

Kai Wucherpennig
Dana-Farber Cancer Institute

KEYNOTE SPEAKER



Bridging the Gap with Creative

Barbara Sosnowski
Pfizer

FEATURED SPEAKER



Creating a Culture of Impact in

Glenn Prestwich
The University of Utah

DISTINGUISHED SPEAKERS



*Panel Discussion: Commercialization of
New Therapeutic Innovations*

Charles Baltic
Needham & Company



*Panel Discussion: Pharmaceutical
Perspectives on the Market*

Brian McVeigh
Glaxo Smith Kline



*Panel Discussion: University and
Foundation Relations*

Simon Bateman
Novartis Pharmaceuticals Corporation



Venture Catalyst: Support for Startups at

Dushyant Pathak
UC Davis



*Session: Commercialization Strategies:
Current Trends and Recent Deals*

Vivian Berlin
Harvard University



Panel Discussion: Venture Capital &

Benjamin Perkins
Ernst & Young Capital Advisors



*Panel Discussion: Biotechnology Transfer
& Licensing*

Josh Bilenker
Loxo Oncology



Panel Discussion: Pharmaceutical

Florian Puehler
Bayer HealthCare – Global Drug Discovery



*Panel Discussion: Biotechnology Transfer
& Licensing*

Wesley D. Blakeslee
Johns Hopkins University



Session: Bridging the Translation Gap

Peter Reinhart
University of Massachusetts

DISTINGUISHED SPEAKERS (cont.)



Panel Discussion: University and Foundation Relations

Benjamin Dibling
UCLA



Panel Discussion: Commercialization of New Therapeutic Innovations

Gary Sclar
Dana-Farber Cancer Institute



Session: Commercialization Strategies: Current Trends and Recent Deals

Howard Fingert
Millennium: The Takeda Oncology Company



The Intersection Between Patent Utility and Breakthrough Science

Jason Sheasby
Irell & Manella



Panel Discussion: University and Foundation Relations

Dana M. Hammill
University of Pennsylvania



Enhancing Credibility of Data Reports by Reproducible Reporting

Keld Sorensen
Siemens Healthcare Diagnostics



Panel Discussion: Commercialization of New Therapeutic Innovations

Karin Immergluck
UCSF



A Patented Novel Therapeutic Target in Multi-stage of Tumorigenesis

Myron R. Szewczuk
Queen's University

Session: Bridging the Translation Gap



Kenneth S. Kilgore
Janssen Pharmaceutical



Panel Discussion: Biotechnology Transfer & Licensing

Ofra Weinberger
Columbia Technology Ventures



Panel Discussion: Venture Capital & Partnerships with Emerging Innovators

Thong Le
Accelerator Corporation




Panel Discussion: Venture Capital & Partnerships with Emerging Innovators

Scott Weiner
Pappas Ventures



Panel Discussion: Biotechnology Transfer & Licensing

Keith Marmer
University of Pennsylvania



Translating Academic Discoveries into New Medicines: Challenges and Opportunities

Leigh Zawel
Pfizer

KEYNOTE SPEAKER



A Review of Pfizer Cell and Gene Therapy Efforts

Marcus Carr
Pfizer



Gene Therapy and Opportunities in Hemophilia as Transformative Technology

John Orloff
Baxter BioScience

DISTINGUISHED SPEAKERS



A Dose Escalation Study of Cyclophosphamide (CTX) to Enhance SB-728-T Engraftment

Dale G. Ando
Sangamo



Overcoming Therapeutic Platform Limitations with Gene Therapies

Michael Naso
Janssen R&D



Session: Emerging Technologies

Charles R. Bridges
Sanger Heart & Vascular Institute



HTA, Funding & Reimbursement of Cell & Gene Therapy – A Global Perspective

Neil Palmer
PDCI Market Access



Preclinical Considerations for Cell and Gene Therapy Products: FDA Perspective

Theresa Chen
US Food and Drug Administration (FDA)



The Value of a Robust AAV Production Platform for Product Development

Harald Petry
uniQure B.V.



Gene Therapy for Inherited Neurodegenerative Diseases

Seng Cheng
Genzyme



Precision Medicine, What It Should Include

Ian Phillips
Keck Graduate Institute of Applied Life Sciences



Orphan Drug Designation And Its Influence On Cell & Gene Therapies

Tim Cote
Cote Orphan Consulting



Functionalizing the Genome Through a Novel Stem Cell-Based Approach

Susan Solomon
NY Stem Cell Foundation



Developing Therapeutics for Neuromuscular Disease: From Basic to Translational Studies

Brian Kaspar
**Nationwide Children's Hospital
Ohio State University College of Medicine**



Rational Basis for Clinical Studies of Systemic Gene Therapy in Muscular Dystrophy

Hansell Stedman
University of Pennsylvania

DISTINGUISHED SPEAKERS (cont.)



Preclinical Development of a Pluripotent Stem Cell Based Therapy for Autoimmune Diseases

Erin A. Kimbrel
Ocata Therapeutics




Genetic Engineering of Novel T Cell Receptors to Generate Anticancer Cellular Therapeutics

Trent Spencer
Emory University School of Medicine



Gene Editing with CRISPR/Cas9: Developing Novel Human Therapeutics

Bill Lundberg
CRISPR Therapeutics



The Rhesus Macaque as a Preclinical Model for Hematopoietic Stem Cell Gene Therapy

John Tisdale
National Institutes of Health



Gene Therapy for Inherited Neuromuscular Diseases

Fulvio Mavilio
Genethon



Transitioning Cell Therapy Product Candidates from Research to Clinical Development: Challenges and Opportunities


Katherine Tsokas
Janssen R&D



A Discussion on the Biotech Space-with Emphasis on Cell and Gene Therapies, and Valuations Shaping Investing

Jason McCarthy
Maxim Group

KEYNOTE SPEAKERS



Immunogenicity Pitfalls in the Development of Therapeutic Protein

Amy S. Rosenberg
FDA

DISTINGUISHED SPEAKERS



ADC Analytics: Challenges & Insights

Conor Barry
Spirogen



Towards Defining the Analytical Fingerprint of Humira®

Czeslaw Radziejewski
AbbVie



Heterogeneous Crystallization: A Process Intensification Technology for the Advanced Manufacture of Drug and Biologic Products


Keith Chadwick
Purdue University



Bristol-Myers
Squibb Company

Session: Cell Therapeutics & Immunotherapy

Surendran Rajendran
Bristol-Myers Squibb



Surface Plasmon Resonance as a Tool for Reagent Screening and Characterization to Enhance Bioanalytical Support for Biotherapeutic Programs

Jia Duo
Bristol-Myers Squibb



The Development and Application of Reference Materials for Protein Particles

Dean Ripple
National Institute of Science and Technology



Integrated Development Environment for the Production of Monoclonal Reference Material

Darryl Davis
Janssen



Session: Bioconjugates & Antibody Drug Conjugates

Tina Roecklein
FDA



Development of a Mass Spectrometric Method for Determination of Excipients in Biologics Formulations

Jason Huang
Bristol-Myers Squibb




Biophysical Tools to Assess Protein Stability in Biologic Drug Products

Geetha Thiagarajan
Merck



Characterization of the Metal Abstraction

Jennifer Laurence
**University of Kansas
Echogen**



Bioconjugate Techniques for the Efficient and Site-specific Modification of Single-chain Proteins and Full-length Antibodies

Andrew Tsourkas
University of Pennsylvania

DISTINGUISHED SPEAKERS (cont.)



Bio-engineering Strategies to Boost the Clinical Impact of Stem Cell-based Therapies

Oren Levy
Harvard Medical School, Brigham and Women's Hospital



Demonstrating Comparability and Similarity on a Small Company Budget

Christina Vessely
Biologics Consulting Group



Bioassays to Quantify a Therapeutic Fc-fusion Protein in Pre-clinical Studies

Kelly Loyet
Genentech



Comparability Assessment of Biotechnology Products

Santosh Yadav
Merck



Evaluation of the Effects of Arginine on Photostability of IgG1 Monoclonal Antibodies Using Biophysical and Biochemical Techniques

Haripada Maity
Eli Lilly and Company



Analytical Development Strategies for Early Stage ADCs

April Xu
Pfizer



Application of NMR Fingerprinting for Structure Mapping of Monoclonal Antibody Therapeutics

John Marino
National Institute of Standards and Technology



Potency Assays for Biopharmaceuticals: A Regulatory Perspective

Baolin Zhang
FDA



Strategies and Challenges in Bioassay Development for Antibody Drug Conjugates

Debra Meyer
Pfizer

KEYNOTE SPEAKER



The Anti-Tumor Effects of the HMGN1 Alarmin

Joost Oppenheim
National Cancer Institute, NIH

FEATURED SPEAKER



STING- Dependent Innate Immune

Glen Barber
University of Miami

DISTINGUISHED SPEAKERS



Regulating Depression by Targeting Th17 Cells

Eleonore Beurel
University of Miami




A Foe No More: Reprogramming NF-kappaB-Driven Inflammation in Cancer Therapy

Pawel Kalinski
University of Pittsburgh



Phosphatidylserine (PS) Receptors, Tyro3, Axl, and Mer (TAMs), Demonstrate Distinct Patterns of Ligand Recognition and Signaling and Contribute Distinctly to the Induction of Immune Escape

Raymond Birge
Rutgers University



T Lymphocytes in the Development of Beige Adipose Tissue

Katia Karalis
Biomedical Research Foundation, Academy of Athens




Tailoring BTK Inhibitor Residence Time Using Reversible Covalent Cysteine Targeting

Michael Bradshaw
Principia Biopharma



IDO2, A Pathogenic Mediator of Inflammation and Autoimmunity

Laura Mandik-Nayak
The Lankenau Institute for Medical Research



Human IL10 Promoter Alleles Determine IL-10 Expression Levels in CD4 T Cells and Susceptibility to Parasitic Infection in Vivo

Jay Bream
Johns Hopkins University



Interferons and Their Antagonists in Disease and Clinical Applications

Sergei Kotenko
Rutgers University



Immature Myeloid Cells Contribute to Tumor Progression by Recruiting IL-17 Producing CD4+ T Cells

Dmitry Gabrilovich
Wistar Institute



Selective BTK Inhibitors Are More Than Just B Cell Kinase Inhibitors

Kevin Otipoby
Biogen Idec

DISTINGUISHED SPEAKERS (cont.)



Strategies for Antagonizing Human IL-23

Grant Gallagher
Humigen



IDO Pathway of Immunomodulation in Cancer and Cancer Therapy

George Prendergast
Lankenau Institute for Medical Research



Bile Acid Regulation of the C3 Alternative Activation Pathway

Glenn Gerhard
Temple University School of Medicine



ABT-122, An anti-TNF/IL-17 Dual Variable Domain Immunoglobulin (DVD-Ig): Mechanisms of Action and Translation to the Clinic

Melanie Ruzek
AbbVie



C GAMP, Where is thy STING?

Andrew Hu
Wistar Institute



Targeting Interferon Regulatory Factor 5 (IRF5) with Cell Penetrating Peptides

Seng-Lai "Thomas" Tan
Serono Research and Development Institute



Inhibiting IL-2 Signaling in Autoimmunity: What Is the Impact on Regulatory T Cells?

David Huss
Biogen Idec



Innate Immune Regulation by STAT-mediated Transcriptional Mechanisms

Stephanie Watowich
MD Anderson Cancer Center

KEYNOTE SPEAKERS



Complexity Matters: A Fly Case for Polypharmacology

Ross Cagan
Icahn School of Medicine at Mount Sinai



Protein Tyrosine Phosphatases: Basic Research to New Therapeutics

Nicholas Tonks
Cold Spring Harbor Laboratory

DISTINGUISHED SPEAKERS



Session: Kinase Inhibitor Design and Overcoming Resistance

Sara Buhrlage
Dana Farber



Dimerization-induced Allosteric Control of RAF Activation

Hugo Lavoie
University of Montreal



Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Adenocarcinoma Through the PI3K mTOR Axis

Alexander M. Búko
Human Metabolome Technologies-America



Ultra-deep and Quantitative Analysis of the Human Phosphoproteome for Precision Cancer Treatment

Shawn Li
University of Western Ontario



ARRY-382: A Selective CSF1R Inhibitor for Immuno-Oncology

Larry Burgess
Array BioPharma



Panel Discussion: Novel Discovery Technologies and Future of Kinase Drug Discovery

David Litchfield
Howard Hughes Medical Institute & University of Washington



Design and Profiling of LRRK2 Kinase Inhibitors

Paul Galatsis
Pfizer Worldwide Research and Development



Large Scale Kinase Profiling for Drug Discovery

Jeffrey R. Peterson
Fox Chase Cancer Center



Discovery and in Vivo Evaluation of the PI3K-delta Inhibitor AMG 319

Felix Gonzalez-Lopez de Turiso
Amgen



Session: Biomarkers in Kinase Drug Discovery


Emanuel F Petricoin
George Mason University

DISTINGUISHED SPEAKERS (cont.)



Session: Kinase Inhibitor Design and Overcoming Resistance

Lee M. Graves
The University of North Carolina @ Chapel Hill



An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity for BRAF-Dependent Tumors

Poulikos Poulikakos
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai



A New Screening Platform for Targeting Protein-Protein Interactions

Jacob Haling
Novartis (GNF)



Regulation of Hematopoiesis by Inositoltrisphosphate 3-Kinase B

Karsten Sauer
The Scripps Research Institute (TSRI)




Session: Kinase Inhibitor Design and Overcoming Resistance

Meenhard Herlyn
Wistar Institute



Phosphorylation of Dazl by MAPKAP kinase 2 regulates spermatogenesis

Todd I. Storchlic
College of Medicine, Drexel University



Calmodulin Regulation of Itk Kinase and Production of the Pro-inflammatory Cytokine IL-17A

Yina H. Huang
The Geisel School of Medicine at Dartmouth



Deciphering Allosteric Mechanisms of BRAF Kinases Regulation and Combating Drug Resistance of Kinase Inhibitors: A Synergistic Perspective from Computational Systems Biology and Biophysical Studies

Gennady Verkhivker
Chapman University



EGF816, an Irreversible Third-generation Mutant-selective EGFR Inhibitor

Yong Jia
Genomics Institute of the Novartis Research Foundation



Investigation of Polypharmacology and Conformation Regulation of RAF Kinases

Chao Zhang
University of California, San Francisco

CONFERENCE DETAILS

REGISTRATION

Early Registration Discount:

20% until July 9, 2015

10% until August 9, 2015

Register for 2 the 3rd goes FREE with coupon code: **RCDVB**

To register online, visit: <https://www.gtcbio.com/register/modern-drug-discovery-development-summit-m3d>

	Commercial	Academic / Govt	Student
Summit	2095.00	1095.00	945.00
2 day pass - 3 conferences	1895.00	895.00	745.00
Individual Conference	1695.00	695.00	545.00

QUICK REGISTRATION - FAX TO (626) 466-4433

First Name: _____ Last Name: _____

Title: _____ Company: _____

Discount Coupon Code: _____

Card #: _____ Exp. Date: _____ CSV #: _____

Cardholder Name: _____

Signature: _____

Billing Address: _____

City: _____ State: _____ Zip: _____

VENUE

Loews Philadelphia Hotel

1200 Market St
Philadelphia, PA 19107
(215) 627-1200

Discounted Group Rate: \$169.00 per night

Discount Deadline: August 10, 2015

Toll Free Reservations: 1-888-575-6397

Mention GTCbio to receive the group rate.

Online Reservations:

https://resweb.passkey.com/Resweb.do?mode=welcome_ei_new&eventID=13876392



PROCEEDINGS

If you are unable to attend the conference you can purchase the proceedings by downloading the order form [here](#). Fill out the order form and fax it to 1 (626) 433-4433 or email it to proceedings@gtcbio.com.